国际药物开发与研究杂志

  • 国际标准期刊号: 0975-9344
  • 期刊 h 指数: 44
  • 期刊引用分数: 59.93
  • 期刊影响因子: 48.80
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Collaboration and Partnerships in Drug Discovery: Advancing Healthcare Together

Sumeet Singh*

Collaboration and partnerships have become increasingly important in drug discovery as the complexity of diseases and the costs associated with drug development continue to rise. This abstract will discuss the role of collaboration and partnerships in advancing healthcare through drug discovery. The paper will explore different types of collaborations, such as public-private partnerships, academic-industry partnerships, and inter-industry partnerships, and highlight their advantages and challenges. The benefits of collaboration in drug discovery, including access to complementary expertise, resources, and technology, will be discussed. Additionally, the importance of open innovation, precompetitive collaborations, and data sharing in accelerating drug discovery and reducing costs will be emphasized. Finally, the paper will examine successful collaborations and partnerships in drug discovery, providing case studies to illustrate how effective collaborations can lead to new treatments and therapies that improve patient outcomes. Overall, the paper will show how collaboration and partnerships are critical to advancing healthcare and drug discovery and highlight the need for continued collaboration in the field.

Keywords

Healthcare; Drug resistance; Collaboration; Research and development; Pharmaceutical industry; Drug discovery

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证